Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zymeworks (ZYME – Research Report) and Nuvectis Pharma (NVCT – Research Report).
Zymeworks (ZYME)
H.C. Wainwright analyst Robert Burns reiterated a Hold rating on Zymeworks today and set a price target of $8.00. The company’s shares closed last Wednesday at $7.66.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Zymeworks is a Moderate Buy with an average price target of $10.17, implying a 33.3% upside from current levels. In a report issued on December 22, Barclays also maintained a Hold rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
Nuvectis Pharma (NVCT)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Nuvectis Pharma today and set a price target of $21.00. The company’s shares closed last Wednesday at $7.50.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Nuvectis Pharma is a Moderate Buy with an average price target of $21.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZYME:
- Zymeworks price target raised to $9 from $7 at Barclays
- Jazz to continue with its rights to Zymeworks’ zanidatamab in key markets
- Zymeworks upgraded to Buy at Jefferies with increased clarity
- Zymeworks upgraded to Buy from Hold at Jefferies
- Zymeworks announces zanidatamab results from HERIZON-BTC-01 trial
